CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s controversial Alzheimer’s disease drug, Aduhelm, to Medicare patients enrolled in approved clinical trials only. In fact, half of those surveyed said CMS' decision would hit how they prescribe the rival drugs waiting in the wings that are also included in CMS' decision.